The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

Ionis licensed this drug to Biogen, which is responsible for ... which was approved by the FDA in April 2023 for amyotrophic ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $54.15, a high estimate of $70.00, and a low estimate of $39.00. A decline of 7.66% from the prior average ...

May 1 (Reuters) - Biogen (BIIB.O), opens new tab beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33% to $563 million in the quarter. Revenue rose 6% to ...